Sekretessinställningar
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • BlankningSe vilka börsnoterade bolag som har offentliggjorda korta positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

UK recognition strengthens Medclair’s position ahead of continued expansion within the NHS

MCLRPressmeddelande2026-11-02 08:00

A recent article in the UK publication The Conversation highlights Newcastle Hospitals, where Medclair’s technology is being used to reduce the climate impact of nitrous oxide. The installation has also been evaluated in a clinical study published in the British Journal of Anaesthesia. With 155 obstetric units across NHS England, Medclair sees significant opportunities to expand its installed base and increase recurring revenue.

The article highlights how the healthcare sector can reduce the climate impact of nitrous oxide without restricting access to effective pain relief during childbirth. At the same time, the clinical study from Newcastle demonstrates significant environmental and occupational health benefits from Medclair's technology. Together, the practical application and the scientific results constitute an important reference for the company's continued expansion in the UK market.

"Newcastle is an important reference for us. Here we have both practical experience and scientific support for our technology. This strengthens our prospects of reaching more hospitals within the NHS. Every new installation contributes to a growing installed base that generates recurring revenue and creates opportunities for further business," says Jonas Lundh, CEO of Medclair.

Scientific study – British Journal of Anaesthesia (2026)
Utilising central and mobile destruction units during labour to reduce ambient nitrous oxide levels: a triple bottom line analysis, British Journal of Anaesthesia, 2026.
https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00356-9/abstract

Article – The Conversation (2026)
https://theconversation.com/greener-maternity-care-starts-with-changing-hospitals-without-putting-pressure-on-pregnant-women-293497

For further information, please contact:
Jonas Lundh, Medclair AB (publ), Phone: +46 76 193 90 90, Email: jonas.lundh@medclair.com

About Us
Medclair is a Swedish cleantech company and a leader in safe and sustainable nitrous oxide management. With operations in twenty countries, Medclair provides innovative solutions that significantly reduce the climate impact of nitrous oxide while improving workplace safety.

The company is listed on NGM Nordic SME. For more information, please visit www.medclair.com.

Attachments
UK recognition strengthens Medclair’s position ahead of continued expansion within the NHS